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Abstract The aim of this study was to evaluate the 4-year
clinical outcomes following regenerative surgery in intrab-
ony defects with either EMD+BCP or EMD. Twenty-four
patients with advanced chronic periodontitis, displaying
one-, two-, or three-walled intrabony defect with a probing
depth of at least 6 mm, were randomly treated with either
EMD+BCP (test) or EMD alone (control). The following
clinical parameters were evaluated at baseline, at 1 year and
at 4 years after regenerative surgery: plaque index, gingival
index, bleeding on probing, probing depth, gingival
recession, and clinical attachment level (CAL). The primary
outcome variable was CAL. No differences in any of the
investigated parameters were observed at baseline between
the two groups. The test group demonstrated a mean CAL
change from from 10.8±1.6 mm to 7.4±1.6 mm (p<0.001)
and to 7.6±1.7 mm (p<0.001) at 1 and 4 years, respectively.
In the control group, mean CAL changed from 10.4±1.3 at
baseline to 6.9±1.0 mm (p<0.001) at 1 year and 7.2±
1.2 mm (p<0.001) at 4 years. At 4 years, two defects in the
test group and three defects in the control group have lost
1 mm of the CAL gained at 1 year. Compared to baseline, at
4 years, a CAL gain of ≥3 mm was measured in 67% of the
defects (i.e., in 8 out of 12) in the test group and in 75% of
the defects (i.e., in 9 out of 12) in the control group. There
were no statistically significant differences in any of the
investigated parameters at 1 and at 4 years between the two
groups. Within their limits, the present results indicate that:
(a) the clinical improvements obtained with both treatments
can be maintained over a period of 4 years, and (b) in two-
and three-walled intrabony defects, the addition of BCP did
not additionally improve the outcomes obtained with EMD
alone. In two- and three-walled intrabony defects, the
combination of EMD+BCP did not show any advantage
over the use of EMD alone.
Keywords Regenerative periodontal therapy . Intrabony
defects . Enamel matrix derivative . Biphasic calcium
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Introduction
The goal of regenerative periodontal surgery is to com-
pletely restore the tooth's supporting apparatus (i.e., root
cementum, periodontal ligament and bone), which have
been lost following periodontal disease or trauma [1].
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Findings from histological studies in animals and humans
have provided evidence for periodontal regeneration fol-
lowing treatment with an enamel matrix derivative (EMD)
[2–11]. Results from controlled clinical studies have
demonstrated that in intrabony defects, open flap debride-
ment (OFD) followed by application of EMD may result in
significantly higher improvements in terms of clinical
attachment level gain and bone fill when compared to
OFD alone [12–16].
Concerns have been expressed regarding the viscous
nature of EMD, which may not be sufficient to prevent
flap collapse in periodontal defects with a complicated
anatomy. A collapse of the mucoperiostal flap may limit
the space available for the regeneration process, thus
yielding less clinical improvements such as clinical
attachment gain and defect fill [17–25]. In order to
overcome this limitation and enhance the clinical outcomes
obtained with EMD alone, different combinations of EMD
and various types of grafting materials such as autogenous
bone (AB) [17], demineralized freeze-dried bone allograft
(DFDBA) [18, 19], anorganic bovine bone mineral
(ABBM) [20–24], bioactive glass [25, 26], or beta
tricalcium phosphate (β-TCP) [27] have been used with
varying degree of success.
Recently, a biphasic calcium phosphate (BCP) with
>99% crystallinity, consisting of 60% hydroxyapatite
(HA) and 40% β-TCP in particulate form has been
introduced as a grafting material in periodontal, peri-
implant and bone defects [28–30]. Findings from animal
studies have indicated that this ratio of HA and β-TCP
may allow for a better control of the resorbability of the
graft material, thus, resulting in accelerated new bone
formation [28, 29].
A recent controlled clinical study has evaluated the
healing of intrabony defects treated with BCP alone, AB
spongiosa, or OFD [30]. At 12 months following surgery,
the results have shown similar clinical improvements in
the groups treated with BCP and AB, which were superior
to those obtained with OFD alone. On the other hand,
results from another controlled, randomized multicenter
clinical study comparing regenerative surgery with EMD
alone to EMD+BCP have shown similar clinical outcomes
following both treatments, without any advantage of the
combination approach [31, 32]. Thus, at present, the
potential advantage of combining EMD with BCP is still
unclear. Moreover, to the best of our knowledge, no data
are available evaluating over a longer period than
12 months the clinical outcomes obtained following this
combination approach.
Therefore, the aim of this controlled clinical study was to
evaluate the 4-year clinical outcomes following regenera-
tive surgery in intrabony defects with either EMD+BCP or
EMD.
Materials and methods
Study design and patient population
The study was designed as a prospective controlled clinical
study with two treatment groups. Twenty-four non-smoking
patients (14 females and 10 males) aged between 34 and 62
diagnosed from advanced chronic periodontitis [33] were
included in this parallel design study (i.e., 12 patients in
each group) after having signed an informed consent. The
study was performed in accordance with the Helsinki
Declaration of 1975, as revised in 2000 and was reviewed
and approved by the local ethical committee (Ethics
Committee Nr.: R-I-003/350/2005). All patients were
treated at the Medical Academy Bialystok, Poland by the
same experienced surgeon (MP). The patients were con-
secutively enrolled in the study when following inclusion
criteria were met: (1) no systemic diseases which could
influence the outcome of the therapy, (2) a good level of
oral hygiene (PI<1) [34], (3) compliance with the mainte-
nance program, (4) presence of one intrabony defect with a
probing depth of at least 6 mm and an intrabony component
of at least 4 mm as detected on the radiographs. The
following clinical parameters were assessed 1 week prior, at
1 year and at 4 years after the surgical procedure using the
same periodontal probe (i.e., UNC 15, Hu-Friedy, Chicago
IL, USA): plaque index (PI) [34], gingival index (GI) [34],
bleeding on probing (BOP), pocket depth (PD), gingival
recession (GR), and clinical attachment level (CAL). The
measurements were made at six sites per tooth: mesioves-
tibular (mv), midvestibular (v), distovestibular (dv), mesio-
lingual (ml), midlingual (l), distolingual (dl) by a masked
and calibrated investigator (JP). Examiner calibration was
performed as follows: five patients, not enrolled in the
study, and showing at least four teeth with probing depths
≥6 mm on at least one aspect of each tooth, were evaluated
by the examiner on two separate occasions, 48 h apart.
Calibration was accepted if measurements at baseline and at
48 h were similar to the millimeter at ≥90%.
The cemento-enamel junction (CEJ) was used as the
reference point. In cases where the CEJ was not visible, a
restoration margin was used for these measurements. The
study reports only the measurements at exactly the same
site (at baseline the deepest) of the selected defect. Pre- and
postoperative radiographs were taken with the long-cone
parallel technique. Randomization was computer-generated
by using a block approach.
Surgical procedure
Following local anesthesia and intracrevicular incisions
mucoperiosteal flaps were raised vestibularly and orally.
Vertical releasing incisions were performed if deemed
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necessary for a better access to the surgical site or to
achieve a better closure. All granulation tissue was removed
from the defects and the roots were thoroughly scaled and
planed by means of hand and ultrasonic instruments.
During surgery, the following measurements were made:
distance from the CEJ to the bottom of the defect (CEJ–
BD), distance from the CEJ to the most coronal extension
of the alveolar bone crest (CEJ–BC). The intrabony
component (INTRA) of the defects was defined as (CEJ–
BD)-(CEJ–BC).
After defect debridement, in both groups, the root
surfaces adjacent to the defects were conditioned for
2 min with ETDA gel (pH 6.7) (Straumann PrefGel™,
Straumann, Basel, Switzerland) to remove the smear layer
[35]. Subsequently, the defects and the adjacent mucoper-
iosteal flaps were thoroughly rinsed with sterile saline to
remove all EDTA remnants.
Following root conditioning, in both the test and the control
group, EMD (Straumann® Emdogain, Straumann, Basel,
Switzerland) was applied onto the root surfaces and into the
defects with a sterile syringe. In the test group, the defects
were additionally filled up with the mixture of EMD+BCP
(Straumann® BoneCeramic, Straumann, Basel, Switzerland).
If deemed necessary, periosteal releasing incisions were
made to allow for a tension-free, coronally adaptation of the
mucoperiosteal flaps. Finally, the mucoperiosteal flaps were
closed with 5–0 monofilament vertical or horizontal
mattress sutures and interrupted sutures.
Postoperative care
All patients received antibiotics for 1 week (3×500 mg
amoxicillin per day) starting 1 h preoperatively. The
postoperative care consisted of 0.2% chlorhexidine rinses
twice a day for 4 weeks. Sutures were removed 14 days
after the surgery. Recall appointments were scheduled
weekly during the first 4 weeks after surgery and every
3 months following the rest of the observation period of
4 years. The recall appointments consisted mainly of
reinforcement of oral hygiene measures and professional
supragingival tooth cleaning.
Statistical analysis
The statistical analysis was performed with the package for
social sciences 12.0 for Windows (SPSS®, Chicago, IL,
USA). The primary outcome variable was the change in
CAL. The secondary variables were PD reduction and GR
change. Only one measurement per tooth, at the deepest site
of the selected defect at baseline, was included into the
calculations. For the statistical evaluation of the changes
from baseline to 1 and 4 years, the paired t test was used.
For the comparisons between the groups, the unpaired t test
was used. The alpha error was set at 0.05.
Power calculation has demonstrated that in order to
detect a statistically significant difference between the two
groups, a much higher number of patients would have been
needed (i.e., 54 patients for each group). The power of the
study, given 1 mm as a significant difference between the
groups, was calculated to be 0.70.
Results
The early wound healing phase was uneventful. Only
adverse events were minor and were limited to usual
Table 1 PI, GI, and BOP at
baseline at 1 and at 4 years
No statistically significant
differences between the
EMD+BCP and EMD groups
were found
PI Plaque index, GI gingival
index, BOP bleeding on probing
Parameter Treatment Baseline 1 Year P value
(baseline—1 year)
4 Years P value (1–4 years)
PI
EMD+BCP (n=12)
Mean (±SD) 0.6±0.2 0.5±0.3 n.s. 0.9±0.8 n.s.
EMD (n=12)
Mean (±SD) 0.7±0.1 0.6±0.2 n.s. 1.0±0.7 n.s.
GI
EMD+BCP (n=12)
Mean (±SD) 1.0±0.2 0.5±0.2 <0.05 1.0±0.8 n.s.
EMD (n=12)
Mean (±SD) 1.1±0.2 0.6±0.3 <0.05 1.0±0.9 n.s.
BOP
EMD+BCP(n=12)
Mean (±SD) 36% 11% <0.05 30% n.s.
EMD (n=12)
Mean (±SD) 38% 12% <0.05 35% n.s.
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postoperative discomfort, swelling, and pain during the first
days following surgery. No adverse reactions against any of
the used regenerative materials were observed. There were
no differences in the gender distribution between the groups
(i.e., eight females and four males in each of the two
groups).
The PI, GI, and BOP for both treatment groups at
baseline, after 1 and 4 years are summarized in Table 1.
Mean PI did not reveal a statistically significant difference
between the two groups at baseline and after 1 and 4 years.
At 4 years, mean PI increased slightly in both groups, but
this difference was not statistically significant compared to
baseline or to the 1 year results.
A statistically significant difference was observed within
both treatment goups, when comparing the 1 and 4 year GI
and BOP to the baseline values (P<0.001). However, there
were no statistically significant differences between the 1-
and 4-year values (Table 1).
There were no differences in terms of defect distribution
and configuration between the two groups (Table 2). The
baseline defect characteristics are presented in Table 3. No
statistically significant difference in the initial depth of the
intrabony component was found between the two groups.
The PD, GR, and CAL at baseline, at 1 and at 4 years are
shown in Table 4. At 1 year, mean PD decreased
statistically highly significantly in both groups (P<0.001)
(Table 4). Between the groups, no statistically significant
difference was found. However, at 4 years, a slight,
statistically not significant increase in PD was measured
in both groups. At 4 years, the PD was still statistically
highly improved compared to baseline (P<0.001) (Table 4).
At 1 and 4 years in both groups, mean GR was
statistically significantly increased compared to baseline
(P<0.01). No statistically significant differences between
the two groups were found at 1 and 4 years (Table 4).
Mean CAL demonstrated statistically significant
improvements in both groups at 1 and at 4 years compared
to the baseline (P<0.001) (Table 4). No statistically
significant differences were observed at 1 and at 4 years
within and between the two treatment groups (Table 4). The
frequency distribution of CAL gain at 1 and 4 years are
depicted in Tables 5 and 6. At 1 year, a CAL gain of ≥3 mm
was measured in 75% of the defects (i.e., in 9 out of 12) in
the EMD+BCP group and in 83% of the defects (i.e., in 10 out
of 12) in the EMD group. At 4 years, a CAL gain of ≥3 mm
was measured in 67% of the defects (i.e., in 8 out of 12) in the
test group and in 75% of the defects (i.e., in 9 out of 12) in the
control group. At 4 years, two defects in the EMD+BCP
group and three defects in the EMD group have lost 1 mm of
the CAL gained at 1 year.
Discussion
The results of this study have shown that treatment of
intrabony defects with both, a combination of EMD+BCP
and EMD alone may lead to statistically significant PD
reductions and CAL gains which can be maintained over a
period of 4 years. However, the statistical analysis has failed to
reveal significant differences between the two treatment
modalities in any of the investigated clinical parameters at 1
and at 4 years. In both groups, a slight, statistically
insignificant, loss of mean CAL was measured between the
1- and 4-year evaluation period. This loss of mean CAL was
due to a CAL loss of 1 mm in two defects in the test group and
in three defects in the control group. Compared to baseline, at
4 years, a CAL gain of ≥3 mm was measured in 67% of the
defects (i.e., in 8 out of 12) in the test group and in 75% of the
defects (i.e., in 9 out of 12) in the control group.
It should, however, be emphasized that the study
does not have the statistical power to rule out the
possibility of a difference between the two groups.
Further studies, with a higher number of patients and
defects would be needed to detect an eventual difference
between the treatments [36]. On the other hand, accord-
ing to the best of our knowledge, at present, there are no
other studies evaluating the clinical performance of a
combination of EMD+BCP over a period of 4 years, and
therefore, the findings may bear clinical relevance despite
Table 2 Distribution and configuration of treated defects
EMD+BCP (N=12) EMD (N=12)
Maxilla 6 5
Mandible 6 7
Anterior teeth 6 5
Premolars 4 5
Molars 2 2
1–2 wall 1 1
2 wall 9 8
3 wall 2 3
Table 3 Baseline defect charac-
teristics expressed in millimeters
(mean±SD)
No statistically significant differ-
ences between the EMD+BCP
and EMD groups were found
Treatment PD (mm) CAL (mm) CEJ-BD (mm) CEJ-BC (mm) INTRA (mm)
EMD+BCP (N=12) 8.8±1.5 10.8±1.6 11.8±1.5 6.2±1.4 5.6±1.4
EMD (n=12) 8.8±1.0 10.4±1.3 11.7±1.2 6.0±1.2 5.7±1.3
P value n.s. n.s. n.s. n.s. n.s.
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the relatively small number of patients and defects. Further-
more, the present results are in line with findings from
previous controlled clinical studies which have failed to show
significant differences in the clinical outcomes following
regenerative surgery using EMD alone or combined with
different alloplastic materials such as bioactive glass, beta
tricalcium phosphate, or bone ceramic graft [26, 27, 31, 32].
In a recent multicenter, randomized, controlled clinical study
comparing treatment with EMD+BCP (test) to EMD alone
(control), the obtained mean CAL gain measured at 1 year
after therapy 1.7±2.1 mm in the test and 1.9±1.7 mm in the
control group, respectively [32]. These values are somewhat
lower than those obtained in the present study where
treatment with EMD+BCP yielded a mean CAL gain of
3.4±1.0 mm, whereas the corresponding value in the EMD
group was 3.5±0.9 mm. These slight differences may, on one
hand, be related to differences in the initial depth of the
defects and, on the other, to differences in defect configura-
tion. It is well documented that in deeper defects, a greater
CAL gain may be achieved [37, 38]. In the present study,
baseline PD was 8.8±1.5 mm in the test group and 8.8±
1.0 mm in the control group, while in the study referred to,
the corresponding values measured 6.9±1.8 mm and 7.1±
1.5 mm, respectively.
Moreover, when comparing the two studies, it needs to
be mentioned that findings from preclinical and clinical
studies have provided evidence for superior healing in so-
called contained-type defects (i.e., three- and two-walled)
compared to “non-contained” (i.e., one-walled or one- and
two-walled) ones [39, 40]. In the study referred to the great
majority of the defects were classified as either one-walled,
combined one- and two-walled or circumferential, while in
the present study, most of the defects displayed a two-
walled configuration [31, 32].
Other key factors which have been shown to profoundly
affect wound healing following conventional and regener-
ative periodontal surgery are infection control and smoking
[38, 41]. The pivotal role of careful patient selection and
strict maintenance program is further supported by the
present findings where the patient population did not
include any smokers, while in both groups, the plaque
and bleeding values remained unchanged throughout the
entire observation period of 4 years.
Table 4 Clinical parameters at
baseline at 1 and at 4 years
No statistically significant
differences between the
EMD+BCP and EMD groups
were found
Parameter Treatment Baseline 1 Year P value
(baseline—1 year)
4 Years P value (1–4 years)
PD
EMD+BCP (n=12)
Mean (±SD) 8.8±1.5 4.3±0.9 <0.001 4.7±0.8 n.s.
EMD (n=12)
Mean (±SD) 8.8±1.0 4.1±0.5 <0.001 4.4±0.8 n.s.
GR
EMD+BCP (n=12)
Mean (±SD) 2.1±1.0 3.2±1.1 <0.01 3.0±1.1 n.s.
EMD (n=12)
Mean (±SD) 1.6±1.0 2.9±0.9 <0.01 2.8±0.8 n.s.
CAL EMD+BCP (n=12)
Mean (±SD) 10.8±1.6 7.4±1.6 <0.001 7.6±1.7 n.s.
EMD (n=12)
Mean (±SD) 10.4±1.3 6.9±1.0 <0.001 7.2±1.2 n.s.
Table 6 Frequency distribution of CAL gains at 4 years in the EMD+
BCP and EMD groups
CAL gain (mm) EMD+BCP (n=12) EMD (n=12)
No. Percent (%) No. Percent (%)
1 1 8
2 3 25 3 25
3 3 25 2 17
4 4 34 7 58
5 1 8
Table 5 Frequency distribution of CAL gains at 1 year in the EMD+
BCP and EMD groups
CAL gain (mm) EMD+BCP (n=12) EMD (n=12)
No. Percent (%) No. Percent (%)
2 3 25 2 17
3 3 25 3 25
4 4 33 6 50
5 2 17 1 8
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A recent human histologic study evaluating the healing
of intrabony defects treated with EMD+BCP revealed
formation of new cementum with an associated periodontal
ligament in six out of the nine biopsies, while formation of
new bone or of a mineralized bone-like tissue around the
graft particles was only occasionally observed. Further-
more, in most specimens, the graft particles were still
present at 9 months following surgery without signs of
resorption or bone formation [42]. These observations
appear to suggest that adding BCP to EMD may not
additionally improve the healing modulated by EMD alone,
thus corroborating the present and previously reported
findings [31, 32].
When interpreting the present results, it should be
pointed to the results from controlled clinical studies
comparing various combination protocols of EMD with
AB, ABBM, or DFDBA to EMD alone and have shown
higher clinical improvements following the combination
approach [17, 18, 22–24]. On the other hand, in most other
studies where EMD was combined with different alloplastic
grafts, no additional benefits were detected [25–27, 31, 32].
Thus, all these findings appear to suggest that the grafting
material itself may also influence the healing process and,
subsequently, the clinical outcomes. However, further
research is necessary to elucidate the exact biological
mechanisms behind these combinations.
Taken together, our results indicate that: (a) the clinical
improvements obtained with both treatments can be main-
tained over a period of 4 years, and (b) in two- and three-
wall intrabony defects, the addition of BCP did not
additionally improve the outcomes obtained with EMD
alone.
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